Literature DB >> 657720

Kinetics of intravenous and intramuscular morphine.

D R Stanski, D J Greenblatt, E Lowenstein.   

Abstract

The disposition of parenteral morphine was assessed in two pharmacokinetic studies. In Study 1, 10 mg of morphine sulfate was administered by intravenous (IV) infusion, intramuscular (IM) injection, or both, to 8 healthy young adult male volunteers. Plasma morphine concentrations were determined by radioimmunoassay in multiple blood samples drawn after each dose. Mean (+/-SE) kinetic parameters following IV morphine were: volume of distribution (Vd), 3.2 (+/- 0.3) L/kg; elimination half-life (t1/2beta), 2.9 (+/- 0.5) hr; clearance, 14.7 (+/- 0.9) ml/min/kg; extraction ratio, 0.70 (+/- 0.04). After IM morphine, peak plasma levels ranged from 51 to 62 ng/ml and were reached within 20 min of injection. The absorption half-life averaged 7.7 (+/- 1.6) min. Systemic availability was 100% complete. In study 2, 4 elderly male patients (61 to 80 yr of age) received 45 to 80 mg of morphine sulfate IV prior to operative repair of an abdominal aortic aneurysm. Morphine pharmacokinetics were determined as described above. Kinetic variables were Vd, 4.7 (+/- 0.2) L/kg; t1/2beta, 4.5 (+/- 0.3) hr; clearance, 12.4 (+/- 1.2) ml/min/kg; extraction ratio, 0.59 (+/- 0.05). Both studies demonstrate that morphine distribution is rapid and extensive and its t1/2beta relatively short. IM morphine is rapidly and completely absorbed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 657720     DOI: 10.1002/cpt197824152

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  53 in total

1.  Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine.

Authors:  Pierre-Louis Toutain
Journal:  AAPS PharmSci       Date:  2002

Review 2.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

3.  A computer-based system for controlling plasma opioid concentration according to patient need for analgesia.

Authors:  H F Hill; R C Jacobson; B A Coda; A M Mackie
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

Review 4.  Interpretation of oral fluid tests for drugs of abuse.

Authors:  Edward J Cone; Marilyn A Huestis
Journal:  Ann N Y Acad Sci       Date:  2007-03-01       Impact factor: 5.691

Review 5.  Pharmacokinetic optimisation of opioid treatment in acute pain therapy.

Authors:  R N Upton; T J Semple; P E Macintyre
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

Review 6.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

7.  Solubility and related physicochemical properties of narcotic analgesics.

Authors:  S D Roy; G L Flynn
Journal:  Pharm Res       Date:  1988-09       Impact factor: 4.200

8.  Effect of cimetidine premedication on morphine-induced ventilatory depression.

Authors:  A M Lam; J L Clement
Journal:  Can Anaesth Soc J       Date:  1984-01

Review 9.  Clinical pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children.

Authors:  K T Olkkola; K Hamunen; E L Maunuksela
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

10.  Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors.

Authors:  Patrick A Singleton; Nurbek Mambetsariev; Frances E Lennon; Biji Mathew; Jessica H Siegler; Liliana Moreno-Vinasco; Ravi Salgia; Jonathan Moss; Joe Gn Garcia
Journal:  J Angiogenes Res       Date:  2010-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.